Chromogranin A Levels in Diagnosis, Treatment and Follow-Up of 42 Patients with Non-Functioning Pancreatic Endocrine Tumours
The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
Background/aims Non-functioning pancreatic endocrine tumours (NFPET) constitute the largest component (35-50%) of pancreatic endocrine tumours. They are characterized by the absence of symptoms of hormone hypersecretion and frequently have clinical manifestations similar to the more common exocrine pancreatic adenocarcinoma. The present studyaims toevaluate the clinical features, diagnostic approach and, in particular, the significance of serum chromogranin A levels (CgA) in the management and outcome of 42 patients with NFPET (from a series of 121 patients with pancreatic endocrine tumours). Methods Twenty-five males and 17 females were included, and the mean age at diagnosis was 52.3 years (range: 26-68 years). The diagnosis for each patient was established by histopathological examination and immunohistochemistry. After the histopathological confirmation of diagnosis and during the follow-up period, patients were evaluated clinically and radiologically (including OctreoScan), whilst fasting gut hormones (including CgA) were also estimated. At diagnosis, all patients were checked for the presence of multiple endocrine neoplasia type I syndrome. The follow-up was complete and ranged from 12 to 86 months (mean: 49 months). Results Dyspepsia (66.5%) and weight loss (47.6%) were the most common symptoms at diagnosis, while in 21.4% of patients tumour lesions were revealed incidentally. Plasma CgA levels were significantly or moderately elevated in all patients with liver metast…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All patients with metastatic disease had elevated CgA concentrations whereas half of patients with localized disease had elevated CgA, strengthening the idea that CgA is more sensitive in disseminated disease compared to localized disease [16,17,18,30,31].”
From Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors (2020) · cites this paper as [31]
Citations
Cites
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
The Chromogranin–Secretogranin Family
Taupenot, L., Harper, K. L., & O'Connor, D. T. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021405 · Cited by 819
Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., & Krenning, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.066 · Cited by 657
Endocrine tumours of the pancreas
Öberg, K., & Eriksson, B. (2005) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2005.06.002 · Cited by 543
Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas
(2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4059-0.x5001-2 · Cited by 449
Panzuto, F., Nasoni, S., Falconi, M., Corleto, V. D., Capurso, G., Cassetta, S., Di Fonzo, M., Tornatore, V., Milione, M., Angeletti, S., et al. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01017 · Cited by 391
Dromain, C., de Baere, T., Lumbroso, J., Caillet, H., Laplanche, A., Boige, V., Ducreux, M., Duvillard, P., Elias, D., Schlumberger, M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.013 · Cited by 389
Arnold, R., Trautmann, M. E., Creutzfeldt, W., Benning, R., Benning, M., Neuhaus, C., Jürgensen, R., Stein, K., Schäfer, H., Bruns, C., et al. (1996) · Gut · doi:10.1136/gut.38.3.430 · Cited by 342
Bodei, L., Cremonesi, M., Zoboli, S., Grana, C., Bartolomei, M., Rocca, P., Caracciolo, M., Mäcke, H. R., Chinol, M., & Paganelli, G. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-1023-y · Cited by 305
Laparoscopic Radiofrequency Ablation of Neuroendocrine Liver Metastases
Berber, E., Flesher, N., & Siperstein, A. E. (2002) · World Journal of Surgery · doi:10.1007/s00268-002-6629-5 · Cited by 236
Research works printed but not linked: 2
- Nikou, 1995, Somatostatin-receptor imaging in the diagnosis and management of gut endocrine tumours, Hell J Gastroenterol, 8, 312
- Ducreux, 2000, The antitumoural effect of the long-acting somatostatin analogue lanreotide in neuroendocrine tumours, Am J Gastroenterol, 95, 3276, 10.1111/j.1572-0241.2000.03210.x · doi:10.1111/j.1572-0241.2000.03210.x · Paper page
Cited by
Falconi, M., Bartsch, D. K., Eriksson, B., Klöppel, G., Lopes, J. M., O'Connor, J. M., Salazar, R., Taal, B. G., Vullierme, M. P., & O'Toole, D. (2012) · Neuroendocrinology · doi:10.1159/000335587 · Cited by 526
Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
Modlin, I. M., Gustafsson, B. I., Moss, S. F., Pavel, M., Tsolakis, A. V., & Kidd, M. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1006-3 · Cited by 387
Strosberg, J. R., Halfdanarson, T. R., Bellizzi, A. M., Chan, J. A., Dillon, J. S., Heaney, A. P., Kunz, P. L., O’Dorisio, T. M., Salem, R., Segelov, E., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000850 · Cited by 373
Halfdanarson, T. R., Strosberg, J. R., Tang, L., Bellizzi, A. M., Bergsland, E. K., O'Dorisio, T. M., Halperin, D. M., Fishbein, L., Eads, J., Hope, T. A., et al. (2020) · Pancreas · doi:10.1097/mpa.0000000000001597 · Cited by 202
Lawrence, B., Gustafsson, B. I., Kidd, M., Pavel, M., Svejda, B., & Modlin, I. M. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.12.001 · Cited by 169
Metadata
- Authors
- Nikou, G. C., Marinou, K., Thomakos, P., Papageorgiou, D., Sanzanidis, V., Nikolaou, P., Kosmidis, C., Moulakakis, A., & Mallas, E.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Hippocration General Hospital (GR)
- Corresponding author
- Nikou, G.C.
- Venue
- Pancreatology
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 8
- Issue
- 4-5
- Pages
- 510-519
- ISSN
- 1424-3903 (ISSN-L)
- OpenAlex
- W1993526737
- Cited by
- 84
- References
- 30
- Citations by year
- 2025: 2 · 2024: 2 · 2022: 2 · 2021: 3 · 2020: 5 · 2019: 4 · 2018: 5 · 2017: 11 · 2016: 7 · 2015: 9 · 2014: 7 · 2013: 6 · 2012: 8
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Pancreatology (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- chromogranin A, serum biomarkers, liver metastasis, octreoscan, somatostatin receptor imaging, tumor progression, treatment response monitoring, multiple endocrine neoplasia type 1, surgical resection, mesenteric metastases, dyspepsia, weight loss, tumor differentiation, prognosis, follow-up
- MeSH terms
- Adult, Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Staging, Pancreatic Neoplasms, Biomarkers, Tumor, Chemoembolization, Therapeutic, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Chromogranin A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Chromogranin A Levels in Diagnosis, Treatment and Follow-Up of 42 Patients with Non-Functioning Pancreatic Endocrine Tumours. https://app.cochat.ai/papers/10.1159/000152000
- The paper
- Nikou, G. C., Marinou, K., Thomakos, P., Papageorgiou, D., Sanzanidis, V., Nikolaou, P., Kosmidis, C., Moulakakis, A., & Mallas, E. (2008). Chromogranin A Levels in Diagnosis, Treatment and Follow-Up of 42 Patients with Non-Functioning Pancreatic Endocrine Tumours. Pancreatology. https://doi.org/10.1159/000152000
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.